The CF33, Vaxinia and Oncarlytics Deal, page-669

Thank you Ben for the many hours of research you carry out on behalf of we IMU shareholders. My day job is too crazy for that but l came across the above which led to a few minutes of big picture musing. There are deals being dine in this space…back to 2021 when Leslie’s dance card was full and there was palpable excitement that a HER Vax deal was imminent. All deals leak in back rooms and we saw the share price move rapidly up. Quiet talk around the market said it was pitched at circa $1. Whatever followed saw no deal and Axel Hoos was voted out by the personal holdings of Paul Hopper et al. Hoos was clearly devastated.

Since then there has been no heads up of any negotiations but we know Leslie has criss crossed America to spruik the IMU platforms. Very recently we watched a Morgan Stanley research report for institutional clients which l can’t link to or quote from due to commercial considerations. It was a huge piece of research based out of the UK by their global pharma analysts. It was devastating to watch …concentrating on the ‘ newest shiniest’ opportunities in oncology and directly in the space IMU is competing in. A number of bio techs, predominantly European got the buy tick. The only problem..the platform being sprouted was, to my understanding, behind the IMU science and in addition was less advanced in the regulatory process.

What is IMU doing wrong in this crucial do or die commercial space? In the pharma marketplace good science is NO guarantee of any commercial success without commercial strategies. IMU seems to have wasted too much opportunity on believing the science will speak and sell itself. Who has Leslie been meeting? The intimation has been that it’s big fund managers…. I want to hear that Leslie has a full diary meeting all the top 5 pharma analysts at the global brokers such as Morgan Stanley team in the UK. Most fund managers will not initiate positions in stocks such as IMU on their own research alone. They’re looking for one or more of the leading analysts in the sector to recommend the stock in order to shift the blame if something goes wrong.

l believe the deal opportunities for HER-Vaxx may have passed and have been superseded by a tsunami of competitors in the same space. BUT …there are big label beverages in the fridge ready to go in the hope I’m absolutely wrong!!

GLTALTH.